Mr. Hugh MacNaught reports

VENTRIPOINT UNVEILS A GLOBAL MODEL FOR A.I.-ENHANCED HEART CARE THROUGH PARTNERSHIP WITH THE NISGA'A VALLEY HEALTH AUTHORITY

Ventripoint Diagnostics Ltd. has formed a transformative partnership with Nisga'a Valley Health Authority (NVHA) that is the next step toward forming a groundbreaking new model for delivering accessible, high-quality heart care powered by artificial intelligence.

The new model follows a hub and spoke design, where a central hub with advanced cardiac capabilities provides support to connected sites in smaller, remote and indigenous communities. Local health care providers can acquire, enhance and read ultrasound scans using VMS+ and transmit them digitally as needed to specialists at the hub for rapid interpretation and consultation.

The Nisga'a Valley Health Authority will serve as the first remote site in this expanding network and will be linked to a regional centre with tertiary and quaternary care capabilities. Future phases are intended to include:

• Additional first nation communities in British Columbia and all of Canada;
• Arctic regions across the country;
• Rural and northern communities worldwide;
• Communities in the Amazon, Africa, India and other regions where MRI (magnetic resonance imaging) access is limited.

This expected results of the model are simple yet profound: delivering advanced cardiac imaging directly to patients -- indigenous and non-indigenous -- without the need for long-distance travel, high costs or extended wait times.

At the core of this model is Ventripoint's VMS+ system, which delivers MRI-level heart measurement accuracy by transforming standard 2-D echocardiograms into 3-D volumetric images. This technology enables precise cardiac assessments to be performed at the point of care, reducing costs and eliminating the need for time-consuming MRI scans. The system is already being used to support diagnosis and monitoring of indications such as congenital heart disease, postsurgical recovery, chemotherapy-related cardiac complications, pulmonary hypertension, heart failure and valve dysfunction.

"Ventripoint is a made-in-Canada innovation already in use across Canada, the United States, Europe and the United Kingdom," said Hugh MacNaught, chief executive officer of Ventripoint. "Through our collaboration with the Nisga'a Valley Health Authority, we are creating a scalable model of heart care that can extend from the Arctic to the Amazon, ensuring that everyone, regardless of geography, has access to advanced diagnostics."

Corinne McKay, chief executive officer , Nisga'a Valley Health Authority, said: "Our responsibility is to ensure that every Nisga'a citizen -- wherever they live -- has access to the highest standard of care, no matter where they live here in the Nass or urban centres of Terrace or Vancouver. Partnering with Ventripoint allows us to explore innovative tools that support more accurate diagnoses, faster treatment decisions and truly patient-centred care right here at home. For NVHA, this collaboration is about more than technology; it is about advancing health sovereignty for the Nisga'a people and strengthening our ability to serve our people with excellence, compassion and cultural integrity."

Ventripoint plans to expand this model throughout Canada and internationally, advancing the goal of universal access to affordable, accurate cardiac diagnostics.

About Ventripoint Diagnostics Ltd.

Ventripoint is an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.